Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025 Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansion SAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41740 Apogee Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-4958665 (Sta ...

Companies have generally managed to perform well against the consensus of earnings forecasts, with around 77% of S&P 500 firms reporting in Q1 considered earnings outperformers. That rate is higher than the normal rate of around 74% recorded in the first three months of a year, with earnings outperformers beating historical trends.The main theme of this quarter’s earnings reports has been artificial intelligence, with companies reporting soaring spending on the technology. Not surprisingly, AI-based and adj ...

SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the closing of its previously announced upsized public offering of 7,790,321 shares of common stock, including the full exercise of th ...

SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price pe ...

Sviatlana Lazarenka/iStock via Getty Images Apogee Therapeutics, Inc. (NASDAQ:APGE) has reported positive results from its phase 1 study using its lead candidate APG777 for the treatment of patients with moderate-to-severe Atopic Dermatitis [AD] and other inflammatory disorders. The last time I went over this biotech, it had not yet reported this data. At the time, I believed that it could create a competitive edge over other IL-13 biologics based on half-life improvement. That is, how long drug exposur ...

Aamulya Apogee Therapeutics: Setting New Benchmarks in Atopic Dermatitis Apogee Therapeutics, Inc. (NASDAQ:APGE) reported Q4 earnings and provided pipeline updates today, inspiring a 30%-plus rally in its stock, breaching all-time highs. The company concentrates on developing biologics for conditions such as COPD and atopic dermatitis [AD]: "designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimi ...

Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to potential for improved clinical responses in induction than currently available biologic therapies and the potential for maintenance dosing of every 3- or 6-months APG777 Phase 1 interim data support advancement of a randomized, placebo-controlled Phase 2 clinical trial in patients with moderate-to-severe atopic der ...

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference ...

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference ...